Business Context and Reporting Period
Company: Amarin Corporation plc
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Amarin is a clinical-stage biopharmaceutical company focused on developing treatments for cardiovascular disease. Its primary asset is AMR101, a prescription-grade omega-3 fatty acid (96% ultra-pure icosapent ethyl) designed to lower triglycerides without raising LDL-C. The company has no commercial revenue and is currently preparing a New Drug Application (NDA) for the U.S. market.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(249.6) million | $(30.6) million |
| Operating Loss | $(45.1) million | $(34.0) million |
| Research & Development Expense | $28.0 million | $20.9 million |
| General & Administrative Expense | $17.1 million | $13.2 million |
| Cash and Cash Equivalents (Year End) | $31.4 million | $52.3 million |
| Warrant Derivative Liability | $230.1 million | $41.5 million |
| Stockholders' Equity (Deficit) | $(202.4) million | $6.6 million |
Note: The 2010 Net Loss includes a non-cash loss of $205.2 million related to the change in fair value of warrant derivative liabilities.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased significantly from $30.6 million in 2009 to $249.6 million in 2010. This was driven primarily by a $205.2 million non-cash loss on the revaluation of warrant derivative liabilities, caused by an increase in the company's stock price.
- Operating Expenses: Operating expenses rose to $45.1 million from $34.0 million. R&D expenses increased by 34% ($7.1 million) due to costs associated with the MARINE and ANCHOR Phase 3 clinical trials. G&A expenses increased by 29.5% ($3.9 million), largely due to warrant-related compensation and stock-based compensation.
- Liquidity: Cash and cash equivalents decreased by $20.8 million to $31.4 million, reflecting cash used in operating activities ($33.9 million) partially offset by financing activities ($13.1 million).
- Equity Position: Stockholders' equity shifted from a positive $6.6 million in 2009 to a deficit of $(202.4) million in 2010, primarily due to the recognition of the warrant derivative liability.
Guidance, Outlook, and Risks
Clinical Progress and Outlook
- MARINE Trial: Top-line results announced in November 2010 showed AMR101 met its primary endpoint, significantly lowering triglycerides in patients with very high levels (≥500 mg/dL) without increasing LDL-C.
- ANCHOR Trial: Enrollment of 702 patients completed in December 2010. Top-line results are expected in Q2 2011. This trial targets patients with high triglycerides on statin therapy.
- Regulatory Strategy: The company expects to submit an NDA to the FDA in Q3 2011 based on MARINE results. ANCHOR results may be added to the NDA to support a broader indication.
- Capital Resources: In January 2011 (subsequent to year-end), the company completed an equity offering raising approximately $98.7 million. Combined with year-end cash, management believes this is sufficient to file the NDA and prepare for commercialization.
Risks and Contingencies
- Internal Controls: Management identified a material weakness in internal control over financial reporting regarding the accounting for complex, non-routine transactions. This weakness persisted through December 31, 2010.
- Profitability: The company has a history of losses and expects to incur continued losses for the foreseeable future. It has no revenue and relies on financing to fund operations.
- Regulatory Approval: There is no assurance that the FDA will approve AMR101, even if clinical trials are successful. The Special Protocol Assessment (SPA) agreements are generally binding but not guaranteed.
- Competition: The company faces competition from GlaxoSmithKline's Lovaza and other omega-3 therapies. AMR101 differentiates itself by being DHA-free to avoid LDL-C elevation.
Key Facts for Investor Verification
- Warrant Liability Impact: Verify the magnitude of the $205.2 million non-cash loss on warrant derivatives and its impact on the reported net loss and equity deficit.
- Cash Runway: Confirm the sufficiency of the $31.4 million year-end cash balance plus the $98.7 million raised in January 2011 to fund the NDA submission and commercial preparation without further dilution.
- Internal Control Weakness: Review the specific remediation steps taken to address the material weakness in internal controls over financial reporting.
- Clinical Trial Results: Monitor the release of ANCHOR trial results (expected Q2 2011) and the subsequent FDA NDA submission timeline (expected Q3 2011).
- Supply Chain: Note the reliance on a single Japan-based supplier for the active pharmaceutical ingredient (ethyl-EPA) and the terms of the supply agreement, including potential termination penalties.